STOCK TITAN

Health Catalyst insider notice: 8,335 shares proposed for sale on 09/02/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) Form 144 shows a proposed sale of 8,335 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 on the NASDAQ, with an aggregate market value of $28,028.10. The filing reports the shares were acquired the same day (09/02/2025) as restricted stock from Health Catalyst as compensation. The filer previously sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10. The total number of outstanding shares is listed as 70,373,625. By signing, the seller represents no undisclosed material adverse information about the issuer.

Positive

  • Proper disclosure: The filer formally reports the proposed sale and past sale as required under Rule 144
  • Transaction details provided: Broker, dates, share counts, gross proceeds and acquisition nature are all disclosed

Negative

  • Same-day acquisition and proposed sale: The 8,335 shares were acquired as restricted stock on 09/02/2025 and are listed for sale the same date
  • No trading-plan date provided: The filing does not state adoption of a Rule 10b5-1 trading plan or instruction date

Insights

TL;DR: Routine insider sale notice; small share amount relative to outstanding stock, disclosed as required.

The filing documents a proposed sale of 8,335 shares via a broker on 09/02/2025 and notes those shares were granted as restricted stock and acquired the same day as compensation. The amounts and values reported are modest versus the 70,373,625 outstanding shares, suggesting limited near-term market impact. Recent past sale on 06/02/2025 of 8,658 shares for $31,470.10 is disclosed, showing prior disposition activity. This is a compliance-driven disclosure under Rule 144 rather than evidence of material company developments.

TL;DR: Filing meets Rule 144 requirements; same-day grant and proposed sale are notable facts to monitor for insider trading policy alignment.

The form confirms the seller represents no undisclosed material information and records compensation-related restricted stock granted and proposed for sale on the grant date. From a governance perspective, the record of grant, prior sale, and broker usage indicates formal reporting compliance. The document does not include a trading plan date or additional context about any 10b5-1 plan, so no conclusions about pre-established instructions can be drawn from this filing alone.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Health Catalyst (HCAT) disclose?

It discloses a proposed sale of 8,335 common shares via Morgan Stanley Smith Barney on 09/02/2025 with aggregate value $28,028.10

When and how were the shares acquired that are being sold?

The 8,335 shares were acquired on 09/02/2025 as restricted stock from Health Catalyst and listed as compensation

Has the filer sold Health Catalyst shares recently?

Yes. The filer sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10

How many Health Catalyst shares are outstanding according to the filing?

The filing lists 70,373,625 shares outstanding

Through which broker will the proposed sale be executed?

The broker listed is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 38th Floor, New York, NY
Health Catalyst

NASDAQ:HCAT

HCAT Rankings

HCAT Latest News

HCAT Latest SEC Filings

HCAT Stock Data

125.19M
63.55M
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
SOUTH JORDAN